Screener
XBI vs IBB
State Street SPDR S&P Biotech ETF vs iShares Biotechnology ETF
Key differences
- XBI costs 0.09% less per year.
- Over the last 3 years, XBI has delivered higher annualized returns.
- IBB has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| XBI | IBB | |
|---|---|---|
| Annual cost (TER) | 0.35% | 0.44% |
| Fund size (AUM) | $8.3B | $7.9B |
| Since | 2006 | 2001 |
| Dividend yield | 0.34% | 0.23% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +66.6% | +39.0% |
| CAGR 3Y | +15.6% | +9.6% |
| CAGR 5Y | +0.9% | +2.7% |
| Sharpe 3Y | 0.54 | 0.38 |
| Volatility 1Y | 25.14% | 19.75% |
| Max drawdown | -63.89% | -39.82% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to XBI and IBB
Explore further